FDA approves Menactra for use as booster immunization
The approval was based on the successful results of an open-lab trial that tested the safety and immunogenicity of Menactra as a booster vaccine in patients who received the initial vaccine years earlier.
David Greenberg, the vice president of U.S. Scientific and Medical Affairs at Sanofi Pasteur, said the FDA approval aligns with recommendations from the Centers for Disease Control and Prevention that teens at the age of 16 receive a booster of meningococcal vaccine.
"The FDA's approval of the Menactra booster vaccination gives health care providers the option to use a meningococcal conjugate vaccine that is approved for both primary and booster immunization," Greenberg said. "With this approval, we hope health care providers are reminded to talk to their teen patients and their parents about the CDC's recommendations, ultimately helping to improve booster immunization rates for teens across the country."
The FDA first approved the Menactra vaccine in 2005, making it the first quadrivalent conjugate vaccine licensed in the U.S. for immunization against meningococcal disease caused by the serotypes within the vaccine.